Alzamend Neuro is a specialty pharmaceutical company engaged in the development and commercialization of patented intellectual property to prevent, treat and cure Alzheimer's disease ("Alzheimer's" or "AD"). Co. has licensed an immunotherapy vaccine peptide that works both as a treatment and vaccine against Alzheimer's and an ionic cocrystal of lithium to mitigate extreme agitation and forestall other deterioration as displayed by patients with up to moderate AD and possibly other neurodegenerative diseases. Co. devotes substantially all its efforts towards research and development of its Technology and raising capital. The ALZN stock yearly return is shown above.
The yearly return on the ALZN stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the ALZN annual return calculation with any dividends reinvested as applicable (on ex-dates).
|